ArticleBMC infectious diseases2019
Third national biobank for population-based seroprevalence studies in the Netherlands, including the Caribbean Netherlands.
Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Trends in Hepatitis B, Hepatitis C, and HIV Seroprevalence in the Netherlands: Insights From Two Decades of Nationwide PIENTER Serosurveys.Journal of viral hepatitis · 2026Article
- Potential value streams of an integrated Canadian serosurveillance network.Canadian journal of public health = Revue canadienne de sante publique · 2026Article
- Proteomic Signatures Over Age Reveal Significant Changes From Infancy Till Late Adulthood.Advanced biology · 2026Article
- The Use of Residual Blood Specimens in Seroprevalence Studies for Vaccine-Preventable Diseases: A Scoping Review.Vaccines · 2025Review
- Twenty Years of Lyme Borreliosis in the Netherlands: Temporal Trends in Seroprevalence and Risk Factors.Microorganisms · 2024Article
- Contact behaviour before, during and after the COVID-19 pandemic in the Netherlands: evidence from contact surveys, 2016 to 2017 and 2020 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response.Influenza and other respiratory viruses · 2024Article
- Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022.Archives of public health = Archives belges de sante publique · 2024Article
- Projecting COVID-19 intensive care admissions for policy advice, the Netherlands, February 2020 to January 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Investigating sources of non-response bias in a population-based seroprevalence study of vaccine-preventable diseases in the Netherlands.BMC infectious diseases · 2024Article
- Quantifying bias introduced by sample collection in relative and absolute microbiome measurements.Nature biotechnology · 2024Article
- Trends inSexually transmitted infections · 2024Article
- Article
- Contact patterns of older adults with and without frailty in the Netherlands during the COVID-19 pandemic.BMC public health · 2023Article
- Seroprevalence ofEpidemiology and infection · 2023Article
- Cytomegalovirus and Epstein-Barr virus co-infected young and middle-aged adults can have an aging-related T-cell phenotype.Scientific reports · 2023Article
- Seroprevalence and Risk Factors of Lyme Borreliosis in The Netherlands: A Population-Based Cross-Sectional Study.Microorganisms · 2023Article
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing.Frontiers in microbiology · 2023Article
- A scenario modelling analysis to anticipate the impact of COVID-19 vaccination in adolescents and children on disease outcomes in the Netherlands, summer 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Higher off-target amplicon detection rate in MiSeq v3 compared to v2 reagent kits in the context of 16S-rRNA-sequencing.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis paper outlines the methodology, study population and response rate of a third large Dutch population-based cross-sectional serosurvey carried-out in 2016/2017, primarily aiming to obtain insight into age-specific seroprevalence of vaccine-preventable diseases to evaluate the National Immunization Programme (NIP). In addition, Caribbean Netherlands (CN) was included, which enables additional research into tropical pathogens.
methodsA two-stage cluster sampling technique was used to draw a sample of Dutch residents (0-89 years) (NS), including an oversampling of non-Western migrants, persons living in low vaccination coverage (LVC) areas, and an extra sample of persons born in Suriname, Aruba and the former Dutch Antilles (SAN). A separate sample was drawn for each Caribbean island. At the consultation hours, questionnaires, blood samples, oro- and nasopharyngeal swabs, faeces, - and only in the Netherlands (NL) saliva and a diary about contact patterns - were obtained from participants. Vaccination- and medical history was retrieved, and in CN anthropometric measurements were taken.
resultsIn total, blood samples and questionnaires were collected from 9415 persons: 5745 (14.4%) in the NS (including the non-Western migrants), 1354 (19.8%) in LVC areas, 501 (6.9%) SAN, and 1815 (23.4%) in CN.
conclusionsThis study will give insight into protection of the population against infectious diseases included in the NIP. Research based on this large biobank will contribute to public health (policy) in NL and CN, e.g., regarding outbreak management and emerging pathogens. Further, we will be able to extend our knowledge on infectious diseases and its changing dynamics by linking serological data to results from additional materials collected, environmental- and pharmacological data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.